About
Building the infrastructure for living medicines.
The Sareen Lab operates at the intersection of stem cell biology, bioengineering, and clinical translation.
Mission
To build the manufacturing infrastructure and cell therapy platforms needed to deliver the next generation of living medicines to patients — at clinical scale, with pharmaceutical-grade quality, and at accessible cost.
Vision
A world where iPSC-derived cell therapies are as routinely manufactured and distributed as small molecule drugs — enabled by autonomous biomanufacturing, universal donor engineering, and deep integration of AI throughout the manufacturing lifecycle.
The PDMO Model
The Cedars-Sinai Biomanufacturing Center operates as a Partnership Development Manufacturing Organization (PDMO) — a novel hybrid model that combines the depth of academic research with the operational rigor of a contract development and manufacturing organization (CDMO).
Unlike traditional CDMOs, the PDMO co-invests in early-stage programs, co-develops manufacturing processes alongside academic and industry partners, and provides IND-enabling support within an academic medical center setting.
Cedars-Sinai Context
The Sareen Lab is embedded within Cedars-Sinai Medical Center in West Hollywood, CA — one of the nation's top-ranked academic medical centers. This position gives us direct access to clinical collaborators, patient populations, regulatory affairs expertise, and a rich pipeline of translational research to advance into manufacturing.
Lab Values
- RigorEvery protocol, every batch, every data point meets the standard of clinical-grade quality.
- TranslationDiscovery has value only when it reaches the patient. We build for clinical use from day one.
- CollaborationThe PDMO model is built on deep partnerships — we co-develop, co-invest, and co-translate.
- AutomationWe systematically eliminate human variability from cell manufacturing through robotics and AI.